Vaxcyte (PCVX) vs Qiagen N.V. (QGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Vaxcyte (PCVX) has outperformed Qiagen N.V. (QGEN) over the past year, gaining 59.9% versus a loss of 4.3%. Over five years, PCVX leads with a +174.3% price change compared with -16.0% for QGEN. Vaxcyte is the larger company by market cap ($9.96 billion vs $9.25 billion), about 1.1 times the size.
Qiagen N.V. pays a dividend yielding 0.81%, while Vaxcyte does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCVX | QGEN |
|---|---|---|
| Share price | $66.96 | $44.79 |
| Market cap | $9.96B | $9.25B |
| 1-day change | +0.39% | -1.88% |
| YTD return | +45.12% | -0.40% |
| 1-year return | +59.92% | -4.29% |
| 5-year return | +174.31% | -15.95% |
| P/E ratio (TTM) | — | 22.74 |
| Forward P/E | — | 17.14 |
| EPS (TTM) | $-7.62 | $1.97 |
| Dividend yield | 0.00% | 0.81% |
| Annual dividend | $0.00 | $0.363 |
| Revenue (latest FY) | — | $2.09B |
| Revenue growth (YoY) | — | +5.65% |
| Net income (latest FY) | $-766.63M | $424.88M |
| Gross margin | — | 62.18% |
| Operating margin | — | 22.29% |
| Net margin | — | 20.33% |
| 52-week high | $90.75 | $57.82 |
| 52-week low | $39.87 | $32.53 |
| Distance from 52-week high | -26.21% | -22.54% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +65.59% | +5.54% |
| Average volume | 1.50M | 2.76M |
| Shares outstanding | 148.81M | 206.50M |
| Employees | 507 | 5,500 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PCVX has outperformed QGEN by 64.2 percentage points over the past year.
About Vaxcyte
PCVX stock →Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 507 employees
About Qiagen N.V.
QGEN stock →Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5,500 employees
PCVX vs QGEN FAQ
Which is bigger, Vaxcyte or Qiagen N.V.?
Vaxcyte (PCVX) is larger, with a market capitalization of $9.96B compared with $9.25B for Qiagen N.V. (QGEN).
Which stock has performed better over the past year, PCVX or QGEN?
PCVX returned +59.92% over the past 12 months, compared with -4.29% for QGEN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Vaxcyte or Qiagen N.V.?
Qiagen N.V. pays a dividend yielding 0.81%, while Vaxcyte does not currently pay a regular dividend.
Are Vaxcyte and Qiagen N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.